The upfront use of ARPI enhancing the pressure of ADT on the AR pathway or causing a significant reduction in circulating and tumour levels of testosterone would avoid the onset of these resistance mechanisms, thus delaying the beginning of the castration resistance phase [37]. This evidence concerns the gene AR and neoplasm.